Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of panitumumab in metastatic colorectal cancer
2010-024490-39Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Rate of patients alive and non-progressed at 2 months. Started May 2011; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2010-024490-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024490-39.